The pharmaceutical company acknowledges that it is not clear if a fourth dose will be necessary, but has announced that it will carry out experiments to determine if it is necessary.

The pharmaceutical company acknowledges that it is not clear if a fourth dose will be necessary, but has announced that it will carry out experiments to determine if it is necessary.

The pharmaceutical company acknowledges that it is not clear if a fourth dose will be necessary, but has announced that it will carry out experiments to determine if it is necessary.

Pfizer-BioNTech vaccine.

Pfizer’s CEO, Albert Bourlahas advanced this Monday that his company could have a vaccine against Covid-19 adapted to the omicron variant ready in March, once it has already begun to manufacture the doses.

“Is vaccine will be ready in March. We are already starting to manufacture some of these units,” Bourla announced in statements to US television CNBC.

The top leader of Pfizer has detailed that this future vaccine, which would also target the other variants of the virus that are circulating, is a request from some countries that “they want it to be ready as soon as possible”.

“The hope is that we get something that offer much better protectionespecially against infections, because the protection against hospitalizations and serious illness is reasonable right now, with current vaccines, as long as the third dose is applied, “he stressed.

Bourla has acknowledged that it is not clear if a fourth dose will be necessarybut has announced that Pfizer will conduct experiments to determine if it is necessary.

For his part, the CEO of Moderna, Stéphane Bancel, also recalled that his company is working on a booster dose that could arrive in the fall and will soon enter clinical trials.

“We are discussing with public health leaders around the world to decide what we think is the best strategy for the possible reinforcement for the fall of 2022. We think it will contain omicron,” Bancel also told CNBC.

Adminartua

Leave a Reply

Your email address will not be published.